^(188)Re-BAC_5对鼻咽癌细胞影响的实验研究

Experimental study of ^(188)Re-BAC_5 radioimmunotherapy on nasopharyngeal carcinoma

采用直接标记法制备188Re-BAC5,并测定标记物的免疫活性,应用噻唑蓝(MTT)法观察188Re-BAC5对体外单层培养的鼻咽癌细胞(CNE-2)的抑制作用。建立鼻咽癌(NPC)肿瘤多细胞微球模型,观察188Re-BAC5对微球生长的抑制和破坏作用。对照组为188Re-BSA、188ReO4。结果显示:188Re-BAC5的标记率在80%以上,标记后的免疫活性分数为61%±15%。MTT法结果表明,188Re-BAC5组的抑瘤率比对照组明显提高(P<0.05);在肿瘤多细胞微球的抑制实验中,188Re-BAC5对微球生长有强烈的抑制和破坏作用,疗效明显优于对照组。本实验提示,188Re-BAC5有可能在对人鼻咽癌的放射免疫治疗中起到良好的作用。

The feasibility of radioimmunotherapy for NPC with 188Re-BAC5, a kind of monoclonal antibody to NPC, was investigated. The 188Re-BAC5 was prepared by direct labeling method and its biological activity was determined. The MTT method was used to determine the inhibition effect of the 188Re-BAC5 on CNE-2 cell line culture, and the destruction effect on CNE-2 multicellular spheroids model was also observed. The control group were 188Re-BSA and 188ReO4-. The biological activity of BAC5 was 1:780000 after purification. The labeling yield of 188Re-BAC5 was above 80%. The immuno-activity of 188Re-BAC5 was 61%±15%. The results of MTT showed that the inhibition ef-fect of 188Re-BAC5 group was much stronger than the control group (P<0.05). In the experiment of tumor multi-cellular spheroids, 188Re-BAC5 had a obvious destruction effect on spheroids, and there was a significant dif-ference between 188Re-BAC5 and the control group. In conclusion, 188Re-BAC5 may serve a possible way in the treat-ment of NPC in the near future.